Coronavirus Diagnosis Prompts Mass General Hospital Doctor To Join Experimental Drug Study
BOSTON (AP) – The new coronavirus made Dr. Jag Singh a patient at his own hospital. His alarm grew as he saw an X-ray of his pneumonia-choked lungs and colleagues asked his wishes about life support while wheeling him into Massachusetts General’s intensive care unit. When they offered him a chance to help test remdesivir, an experimental drug that’s shown promise against some other coronaviruses, “it did not even cross my mind once to say ‘no,’” said Singh, a heart specialist. Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks. Interest has been so great that the U.S. National Institutes of Health is expanding its study, which has nearly reached its initial goal of 440 patients. The drug’s maker, California-based Gilead Sciences, is quickly ramping up its own studies, too. “I would enroll my family in a heartbeat” if the need arose, said Dr. Libby Hohmann, who placed Singh and nearly 30 others in the NIH one at Mass General. To have no approved medicines for COVID-19 now is “kind of terrifying,” she said. For most people, the new coronavirus causes mild or moderate symptoms, which can include fever and cough but sometimes pneumonia requiring hospitalization. The risk of death is greater for older adults and people with other health problems. Remdesivir is given through an IV. It’s designed to interfere with...
Publication date: Available online 4 June 2020Source: MycoscienceAuthor(s): Naozumi Kondo, Toshiyuki Tokiwa, Kotaro Sato, Satoshi Ōmura, Kenichi Nonaka
Publication date: Available online 3 June 2020Source: Life SciencesAuthor(s): Nehla Banu, Sandeep Surendra Panikar, Lizbeth Riera Leal, Annie Riera Leal
Publication date: Available online 2 June 2020Source: Life SciencesAuthor(s): Fereshteh Yazdanpanah, Michael R. Hamblin, Nima Rezaei
Publication date: Available online 1 June 2020Source: Life SciencesAuthor(s): Abhjieet Pandey, Ajinkya Nitin Nikam, Ajjappla Basavraj Shreya, Sadhana P. Mutalik, Divya Gopalan, Sanjay Kulkarni, Bharath Singh Padya, Gasper Fernandes, Srinivas Mutalik, Ruth Prassl
Publication date: 1 September 2020Source: Life Sciences, Volume 256Author(s): Fedor Simko, Russel J. Reiter
Authors: Frost DW, Shah R, Melvin L, Galán de Juana M, MacMillan TE, Abdelhalim T, Lai A, Rawal S, Cavalcanti RB PMID: 32493744 [PubMed - as supplied by publisher]
Authors: Boodman C, Lagacé-Wiens P, Bullard J PMID: 32493742 [PubMed - as supplied by publisher]
Authors: Mishra S, Kwong JC, Chan AK, Baral SD PMID: 32493741 [PubMed - as supplied by publisher]
Authors: Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, He N, Wu Z, Zhang Q, Gong X, Tang Q, Du X, Ying Y, Xu X, Zhang Y, Liu J, Li Y, Shen N, Couban RJ, Ibrahim QI, Guyatt G, Zhai S Abstract BACKGROUND: Antiviral medications are being given empirically to some patients with coronavirus disease 2019 (COVID-19). To support the development of a COVID-19 management guideline, we conducted a systematic review that addressed the benefits and harms of 7 antiviral treatments for COVID-19. METHODS: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PubMed and 3 Chinese databases (CNKI, WA...
Publication date: Available online 4 June 2020Source: Protein Expression and PurificationAuthor(s): Dominic Esposito, Jennifer Mehalko, Matthew Drew, Kelly Snead, Vanessa Wall, Troy Taylor, Peter Frank, John-Paul Denson, Min Hong, Gulcin Gulten, Kaitlyn Sadtler, Simon Messing, William Gillette
More News: Anxiety | Cardiology | Children | China Health | Coronavirus | Cough | COVID-19 | Emergency Medicine | Genetics | Health | Heart | Hospitals | Infectious Diseases | Intensive Care | Japan Health | Medical Ethics | MERS | National Institutes of Health (NIH) | Pneumonia | SARS | Science | Singapore Health | Sports Medicine | Study